Skip to main content
. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2

4. SD of BP at baseline vs endpoint in trials with DBP entry criteria.

    ACE Inhibitor Placebo
Weighted mean SD of SBP At baseline (SD) 14.8 (3.0) 14.9 (2.8)
  At endpoint (SD) 16.6 (3.1) 16.8 (3.0)
t‐test baseline vs endpoint p = 0.06 p = 0.05
Weighted mean SD of DBP At baseline (SD) 5.1 (1.5) 5.1 (1.6)
  At endpoint (SD) 9.0 (1.7) 8.9 (1.8)
t‐test baseline vs endpoint p < 0.0001 p < 0.0001